Live Breaking News & Updates on Available Methods

Stay updated with breaking news from Available methods. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial

WILMINGTON, Del. (BUSINESS WIRE) Jun 2, 2024 ....

United States , United Kingdom , Chelsea Tressler , Daiichi Sankyo , Brendan Mcevoy , American Society Of Clinical Oncology , World Health Organization , Lungevity Foundation , Lung Ambition Alliance , International Agency For Research On Cancer , Archives Pathology Lab , Single Institution Study , Plenary Session , Clinical Oncology , Annual Meeting , New England Journal , Prescription Information , Patient Information , South America , Rare Diseases , International Agency , Lung Fact , Accessed May , Cancer Biomarkers , Present Status , Clinical Oncology Provisional Opinion ,

TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial

First EGFR inhibitor and targeted treatment to demonstrate progression-free survival benefit in Stage III setting

. ....

United States , United Kingdom , Suresh Ramalingam , Susan Galbraith , Cerner Cancermpact , Daiichi Sankyo , International Agency For Research On Cancer , American Cancer Society , Lung Ambition Alliance , Winship Cancer Institute Of Emory University , Lungevity Foundation , Single Institution Study , World Health Organisation , Executive Director , Winship Cancer Institute , Emory University , Executive Vice President , Prescription Information , Patient Information , South America , Rare Diseases , International Agency , Lung Fact , Accessed February , What Is Lung , Clinical Oncology Provisional Opinion ,

Complying with the Children's Online Privacy Protection Rule; FTC's Proposed Updates | Kilpatrick

On December 20, 2023, the Federal Trade Commission (FTC) published a Notice of Proposed Rulemaking (Proposed Rule) seeking to update the Children’s Online Privacy Protection Act. ....

School For Educational Services , School Authorization , Federal Trade Commission , Proposed Rulemaking , Proposed Rule , Online Privacy Protection Act , Audience Sites , Directed Standard Changes , Personal Information , Third Parties , Available Methods , Obtaining Opt In Consent , Educational Services , Authorized Education Purpose , Security Requirements , Deletion Requirements , Operations Exception , Contact Exception , Online Privacy Protection Rule ,

TAGRISSO® (osimertinib) Plus Chemotherapy Extended Median Progression-free Survival by Nearly 9 Months in EGFR-mutated Advanced Lung Cancer in FLAURA2 Phase III Trial

Combination reduced the risk of disease progression by 38% versus TAGRISSO monotherapy, the current 1st-line global standard of care

. ....

United Kingdom , United States , Daiichi Sankyo , Single Institution Study , Lung Ambition Alliance , Company On Social Media Astrazeneca , Lungevity Foundation , World Health Organisation , International Agency For Research On Cancer , Presidential Symposium , International Association , Lung Cancer , Prescribing Information , Patient Information , South America , Rare Diseases , Social Media , International Agency , Lung Fact , Accessed August , Small Cell , Histological Samples , Non Small Cell Lung Cancer , Systematic Review , Intj Clin Exp , Clinical Oncology Provisional Opinion ,